Drugs / DX243
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07637981 | May 2026 → Oct 2027 expected | presbycusis | Dendrogenix | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-07-03 | Dendrogenix | Results DX243 demonstrates beneficial effects in preclinical models of ischemic stroke. dendrogenix.com ↗
In a mouse model of stroke (middle cerebral artery occlusion-MCAO), a single injection of DX243 administered at the time of reperfusion significantly reduces cerebral infarct volume and preserves motor coordination assessed 48 hours after the stroke. |
| 2026-05-20 | Dendrogenix | Results DX243 shows sustained neuroprotection of key auditory circuits involved in Age-Related Hearing Loss. dendrogenix.com ↗
Dendrogenix reports the publication of new preclinical results highlighting the ability of DX243 to protect the most vulnerable auditory circuits from age-related degeneration. |
| 2026-01-29 | Dendrogenix | Results Dendrogenix announces positive Phase 1 results for DX243 and prepares to launch a Phase 2a clinical trial in age-related hearing loss dendrogenix.com ↗
Dendrogenix, an innovative biotechnology company based in Liège (Belgium) announced today positive results from its first Phase 1 clinical trial evaluating its drug candidate DX243. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-03 | Dendrogenix | DX243 demonstrates beneficial effects in preclinical models of ischemic stroke. dendrogenix.com ↗ |
| 2026-06-03 | Dendrogenix | Dendrogenix doses first patient in Phase IIa with DX243 for age-related hearing loss. dendrogenix.com ↗ |
| 2026-05-20 | Dendrogenix | DX243 shows sustained neuroprotection of key auditory circuits involved in Age-Related Hearing Loss. dendrogenix.com ↗ |
| 2026-01-29 | Dendrogenix | Dendrogenix announces positive Phase 1 results for DX243 and prepares to launch a Phase 2a clinical trial in age-related hearing loss dendrogenix.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DX243 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07637981 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT07637981 ↗ |